Cargando…
Efficacy and safety of different interventions in castration resistant prostate cancer progressing after docetaxel-based chemotherapy: Bayesian network analysis of randomized controlled trials
Background: Most patients receiving docetaxel-based chemotherapy for castration resistant prostate cancer (CRPC) will eventually progress, and the optimal interventions for these patients are controversial. The objective of our study is to evaluate the clinical efficacy and safety of pharmacological...
Autores principales: | Zhao, Yue, Huang, Hao, Chen, Changhao, Liu, Hao, Liu, Hongwei, Su, Feng, Bi, Junming, Lam, Thomas B., Li, Jiaping, Lin, Tianxin, Huang, Jian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5858491/ https://www.ncbi.nlm.nih.gov/pubmed/29556327 http://dx.doi.org/10.7150/jca.22365 |
Ejemplares similares
-
Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic
Castration-Resistant Prostate Cancer
por: Maia, Manuel Caitano, et al.
Publicado: (2017) -
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer
por: Lin, H-M, et al.
Publicado: (2014) -
Predictive Factors for Premature Discontinuation of Docetaxel-Based Systemic Chemotherapy in Men With Castration-Resistant Prostate Cancer
por: Park, Seung Chol, et al.
Publicado: (2013) -
Prognostic factors and risk stratification in patients with castration-resistant prostate cancer receiving docetaxel-based chemotherapy
por: Yamashita, Shimpei, et al.
Publicado: (2016) -
KDM5D predicts response to docetaxel chemotherapy in metastatic castration resistant prostate cancer patients
por: Schäfer, Georg, et al.
Publicado: (2021)